Renal tolerance of cefpirome (HR 810), a new cephalosporin antibiotic.
An open study was carried out in ten healthy, male volunteers in order to investigate the renal tolerance of cefpirome (HR 810), a new cephalosporin antibiotic. Subjects received a single dose of 1.0 g of cefpirome and then repeated doses of 1.0 g of cefpirome twice daily for five days. Urine was collected in several fractions during the study and the urine excretion, excretions of creatinine, N-acetyl-beta-D-glucosaminidase, gamma glutamyltransferase, alanine aminopeptidase and lactate dehydrogenase were calculated in 12-hour fractions. Serum creatinine (using an enzymatic method), beta 2-microglobulin concentrations and creatinine clearance were also determined. Based on the findings of these renal enzymes, renal tolerance was good. This was also confirmed by creatinine clearance calculations and follow-up of serum beta 2-microglobulin levels. Cefpirome showed good renal tolerance without any signs of nephrotoxicity in this study with the methods used.
D000118:Acetylglucosaminidase / Q000652:urine; D000328:Adult; D000626:Aminopeptidases / Q000652:urine; D018826:CD13 Antigens; D002511:Cephalosporins / Q000009:adverse effects*; D004796:Clinical Enzyme Tests; D003404:Creatinine / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis; D007770:L-Lactate Dehydrogenase / Q000652:urine; D008297:Male; D008875:Middle Aged; D001613:beta 2-Microglobulin / Q000378:metabolism; D005723:gamma-Glutamyltransferase / Q000652:urine; D000097572:Cefpirome
D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens; D002511:Cephalosporins; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D001613:beta 2-Microglobulin; D005723:gamma-Glutamyltransferase; D000097572:Cefpirome